![]() |
![]() |
|
Back to 2007 Program and Abstracts
PGE2 in Pancreatic Cyst Fluid Differentiates IPMN from Mucinous Cystadenoma and May Predict Degree of IPMN Dysplasia C. Max Schmidt*1,5, Michele T. Yip-Schneider1,2, Matthew C. Ralstin3, Sarah Dutkevitch1, Sabrina C. Wentz1, John M. Dewitt4, Thomas J. Howard1, Lee Mchenry4, Keith D. Lillemoe1 1Surgery, Indiana University School of Medicine, Indianapolis, IN; 2Indiana University Cancer Center, Indianapolis, IN; 3Indiana University School of Medicine, Indianapolis, IN; 4Gastroenterology, Indiana University School of Medicine, Indianapolis, IN; 5Richard L. Roudebush Veterans Affairs Medical Center, Indianapolis, IN
Introduction: Management of pancreatic mucinous cyst may be contingent upon its identity as intraductal papillary mucinous neoplasm (IPMN) or mucinous cystadenoma. IPMNs, although unifocal on presentation, develop multifocality and cyst size is not a predictor of malignant potential. Conversely, mucinous cystadenomas are rarely multifocal and thus amenable to segmental resection/enucleation, and cyst size is a predictor of malignant potential. Distinguising between IPMN and mucinous cystadenoma is clinically important, necessitating novel biomarkers of degrees of IPMN dysplasia. Preliminary studies suggest a positive correlation of cyclooxygenase-2 (COX-2) expression with IPMN dysplasia. We hypothesized that prostaglandin E2 (PGE2), a measure of cyclooxygenase activity, distinguishes between IPMN and mucinous cystadenoma and may be a biomarker of IPMN dysplasia.
Back to 2007 Program and Abstracts |
About the SSAT |
Membership |
Pay Membership Dues |
Meetings & Education |
Awards |
Foundation |
Publications |
Advocacy |
Donate Today |
![]()
|
|
![]()
|